|

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

RECRUITINGPhase 2/3Sponsored by Western Institute for Veterans Research
Actively Recruiting
PhasePhase 2/3
SponsorWestern Institute for Veterans Research
Started2024-03-25
Est. completion2025-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT05625633

Summary

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Must be able to understand and provide written informed consent
2. Age 18 or older
3. Clinical diagnosis of cutaneous warts
4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)

Exclusion Criteria:

1. Untreated cutaneous warts
2. Anogenital warts
3. Oral warts
4. Treatment for cutaneous warts in the past 4 weeks
5. Active acute illness
6. Immunosuppression
7. Known hypersensitivity to HPV vaccination
8. Subjects may not receive any other investigational treatment
9. Pregnancy or planned pregnancy during the study period

Conditions2

CancerWarts

Locations2 sites

University of Utah Midvalley Health Center
Salt Lake City, Utah, 84107
Lowell Nicholson, MD801-581-2121lowell.nicholson@hsc.utah.edu
VA Salt Lake City Health Care System
Salt Lake City, Utah, 84148
Jamie Rhoads, MD801-582-1565jamie.rhoads@hsc.utah.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.